Tetrakis(hydroxymethyl)phosphonium sulfate

• Identification
• Experimental evidence
• Physicochemical properties
• ADMET properties
• Chemical-gene interaction
• Descriptors
• Presence in chemical regulation or guideline
• Presence in human biospecimen

Literature identifier	Study type	Test dosage	Effective dosage	Endocrine-mediated endpoints	Systems-level perturbations
PMID:12748709	IVR	5 mg/kg	5 mg/kg	Hyperplasia in adrenal gland	Metabolic endocrine-mediated perturbations
	IVR	10 mg/kg	10 mg/kg	Affects hematopoiesis of spleen	Immunological endocrine-mediated perturbations
	IVR	10 mg/kg	10 mg/kg	Hyperplasia in adrenal gland	Metabolic endocrine-mediated perturbations
	IVR	10 mg/kg	10 mg/kg	Affects morphology of hepatocytes	Hepatic endocrine-mediated perturbations
	IVR	10 mg/kg	10 mg/kg	Hyperplasia of bone marrow	Immunological endocrine-mediated perturbations
	IVR	10 mg/kg	10 mg/kg	Affects hematopoiesis of liver	Hepatic endocrine-mediated perturbations;Immunological endocrine-mediated perturbations
	IVR	20 mg/kg	20 mg/kg	Affects morphology of hepatocytes	Hepatic endocrine-mediated perturbations
	IVR	1200 mg/kg	-	No significant effects observed	-
	IVR	7.5 mg/kg	-	No significant effects observed	-
	IVR	600 mg/kg	-	No significant effects observed	-
	IVR	50 mg/kg	-	No significant effects observed	-
	IVR	30 mg/kg	-	No significant effects observed	-
	IVR	150 mg/kg	-	No significant effects observed	-
	IVR	12.5 mg/kg	-	No significant effects observed	-
	IVR	75 mg/kg	-	No significant effects observed	-
	IVR	25 mg/kg	-	No significant effects observed	-
	IVR	15 mg/kg	-	No significant effects observed	-
	IVR	3.75 mg/kg	-	No significant effects observed	-
	IVR	300 mg/kg	-	No significant effects observed	-
	IVR	40 mg/kg	40 mg/kg	Affects morphology of hepatocytes	Hepatic endocrine-mediated perturbations
	IVR	60 mg/kg	60 mg/kg	Affects morphology of hepatocytes	Hepatic endocrine-mediated perturbations

---

DISCLAIMER

We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.